Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

  1. Rugo, H.S.
  2. Bardia, A.
  3. Marmé, F.
  4. Cortés, J.
  5. Schmid, P.
  6. Loirat, D.
  7. Trédan, O.
  8. Ciruelos, E.
  9. Dalenc, F.
  10. Gómez Pardo, P.
  11. Jhaveri, K.L.
  12. Delaney, R.
  13. Valdez, T.
  14. Wang, H.
  15. Motwani, M.
  16. Yoon, O.K.
  17. Verret, W.
  18. Tolaney, S.M.
Aldizkaria:
The Lancet

ISSN: 1474-547X,  0140-6736

Argitalpen urtea: 2023

Alea: 402

Zenbakia: 10411

Orrialdeak: 1423-1433

Mota: Artikulua

DOI: 10.1016/S0140-6736(23)01245-X GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus